in Xenopus oocytes and analyzed using two-electrode voltage clamp. GABA EC 50 , BZD EC 50 and BZD maximal potentiation were measured. This data, combined with previous radioligand binding data describing the mutations' effects on BZD apparent binding affinities , were used to distinguish residues within the BZD pocket that contribute to BZD efficacy and BZD binding. We identified six residues whose mutation altered BZD maximal potentiation of I GABA (BZD efficacy) without altering BZD binding apparent affinity, three residues whose mutation altered binding but had no effect on BZD efficacy, and four residues whose mutation affected both binding and efficacy. Moreover, depending on the BZD ligand, the effects of some mutations were different indicating that the structural mechanisms underlying the ability of BZD ligands with divergent structures to potentiate I GABA are distinct.
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INTRODUCTION
Benzodiazepines (BZDs) are commonly used in the treatment of sleep disorders, anxiety, muscle spasms, seizure disorders, and some forms of depression (Mohler et al., 2002) . They exert their therapeutic actions by binding to the γ -aminobutyric acid type A receptor (GABA A R) and modulating GABA-induced chloride current (I GABA ). The GABA A R is a heteropentameric, ligand-gated ion channel and belongs to the cys-loop superfamily of receptors that includes the 5HT 3 receptor, glycine receptor and nicotinic acetylcholine receptor (nAChR) (Ortells and Lunt, 1995) . The most common GABA A receptor subtype found in the brain is comprised of α 1 , β 2 , and γ 2 subunits in a ratio of 2α:2β:γ (Baumann et al., 2002; Chang et al., 1996; Farrar et al., 1999; Sieghart and Sperk, 2002) . The BZD binding site is located in the extracellular domain of the receptor at the interface of the α and γ subunits (Fig. 1A) , and is formed by six noncontiguous regions historically designated loops A-F (Fig. 1B) (Boileau et al., 2002; Boileau et al., 1998; Sigel and Buhr, 1997) .
Ligands that bind to the BZD site can act as negative modulators that inhibit I GABA (BZD inverse agonists), as positive modulators that potentiate I GABA (BZD agonists) or as zero modulators that bind yet have no affect on I GABA (BZD antagonists) . While multiple studies have identified residues that are involved in mediating the apparent binding affinity (K d ) of BZD-site ligands including classical, [1, 4] benzodiazepines (Boileau et al., 2002; Derry et al., 2004; Kucken et al., 2000; Wieland and Luddens, 1994) , cyclopyrrolones (e.g. eszopiclone) (Davies et al., 2000; and imidazopyridines (e.g. zolpidem) (Buhr et al., 1996; Schaerer et al., 1998) , much less is known about the M OL #69542 5 structural determinants that couple their binding to modulation of I GABA and govern whether a BZD-site ligand is a positive modulator, zero modulator or negative modulator (i.e. BZD efficacy).
In general, it is believed that BZDs exert their allosteric effects by either shifting the GABA A R closed to open state channel equilibrium (Campo-Soria et al., 2006; Downing et al., 2005; Rusch and Forman, 2005) or by altering the receptor's microscopic binding affinity for GABA (Goldschen-Ohm et al., 2010; Lavoie and Twyman, 1996; Mellor and Randall, 1997; Rogers et al., 1994; Thompson et al., 1999; Twyman et al., 1989) . Regardless of the mechanism, BZD binding to the receptor is the initial perturbation that triggers structural rearrangements in the protein that result in modulation of GABA A R function. Residues that line the BZD binding site pocket likely have different roles in this process. Some residues may directly interact with the ligand and contribute to its binding affinity, some may stabilize binding site structure, whereas others may mediate local conformational movements important for coupling BZD binding to modulation of I GABA . Identifying the residues that are involved in these actions is critical for elucidating the structural mechanisms that govern the pharmacological effects of these drugs and will help predict the therapeutic effects of new drugs.
Previously, we identified residues within the BZD binding site that were important for high-affinity binding of flumazenil (Ro15-1788), eszopiclone (ESZ) and zolpidem (ZPM) ). Here, we tested the hypothesis that residues in the BZD binding site are also crucial for determining BZD efficacy. We measured the effects that 22 single cysteine mutations (Fig. 1D) We focused on residues that have not been extensively examined previously and for which the effects of mutating the residue on BZD apparent binding affinities were known. We identified six residues whose mutation solely altered BZD efficacy suggesting that they are part of the allosteric pathway involved in coupling BZD binding to modulation of GABA A R function. We identified three residues that when mutated only altered BZD binding affinity suggesting that they are important for ligand docking. Expression in Xenopus laevis oocytes. Expression of WT and mutant GABARs was performed as described previously . Capped cRNA from NotI-digested cDNA was in vitro transcribed using the mMessage mMachine T7 kit (Ambion, Austin, TX). X. Laevis oocytes were harvested and prepared as described previously (Boileau et al., 1998) . Oocytes were injected within 24h of treatment with 27nl cRNA (1-15pg/nl/subunit) in the ratio 1:1:10 (α:β:γ) (Boileau et al., 2002 ) and stored at 16ºC in ND96 buffer (in mΜ: 96 NaCl, 2KCl, 1MgCl 2 , 1.8CaCl 2 , 5 HEPES, pH 7.2) supplemented with 100µg/ml BSA until used for electrophysiological recordings.
Two-electrode voltage clamp.
Electrophysiological recordings were performed as described previously . Oocytes were held at -80mV Concentration-response analysis. GABA concentration-response curves were determined as described previously . Six to twelve concentrations of GABA were used for each GABA EC 50 value determination. Each current response was scaled to a low, non-desensitizing concentration of GABA (EC 1-5 ) applied just before the test concentration to correct for any drift in I GABA responsiveness over the course of the experiment. Concentration-response data were fit by the following
n )], where I is the peak response to a given drug concentration, I max is the maximum amplitude of current, EC 50 is the drug concentration that produces that half-maximal response, [A] is drug concentration, and n is the Hill coefficient using Prism V.4.0 (GraphPad Software, San Diego, CA). The EC 50 values in Table 1 for Log (EC 50 ) values were used for statistical analyses.
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RESULTS
We previously made 22 single cysteine mutations throughout the BZD binding site in loops A (D97C, F99C), B (G157C, A160C, T162C), and C (G200C, V202C, S204C, S205C, T206C, Y209C, V211C) of the α 1 subunit and loops E (T126C, M130C, R132C, L140C, T142C, R144C) and F (R185C, E189C, R194C, R197C) of the γ 2 subunit ( Fig. 1 ) and examined the effects of these mutations on BZD binding using competitive radioligand binding experiments (see Table 2 for mut/WT K i values) . The mutations in the γ Loop F region had no effect on BZD apparent binding affinity, whereas at least one mutation in each of the not others suggesting that residues in these regions help define BZD selectivity ). Here, we tested the hypothesis that residues in the BZD binding site are not only important for BZD binding but also play a role in defining BZD efficacy. Cysteine mutant subunits were co-expressed with wild type (WT) subunits in Xenopus laevis oocytes to form
2 GABA A receptors and analyzed using two-electrode voltage clamp. We examined the effects the mutations had on GABA-activated currents (I GABA ) and on FZM, ESZ and ZPM modulation of EC 15 I GABA .
Effects of cysteine substitutions on I GABA
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All of the mutant subunits assembled into functional GABA A Rs ( Table 1) .
Effects of cysteine substitutions on FZM modulation of I GABA
We measured the effects the mutations had on the abilities of three structurally different BZD-site positive modulators, FZM (1,4 benzodiazepine), ESZ (cyclopyrrolone) and ZPM (imidazopyridine) to potentiate GABA (EC 15 ) currents.
Current traces and dose response curves for BZD potentiation of I GABA are depicted in receptors was not detectable using a filtration-based radioligand binding assay ( Table 2 ).
The inability to detect radioligand binding is likely due to inherent limitations of filtration binding assays, which preclude measuring binding when the affinity of the radioligand is much above 100nM. Given that we can measure BZD modulation of I GABA for these mutant receptors, these drugs bind to the mutant receptors, likely with lower apparent affinity. The rightward shifts in the BZD concentration responses are consistent with this idea. In the γ 2 subunit, mutations at R144 in loop E and R197 in loop F significantly reduced ESZ maximal potentiation. While α A160C significantly reduced ESZ potentiation of I GABA (i.e. ESZ efficacy), this mutation had little to no effect on ESZ apparent binding affinity (K i , Table 2 ).
Effects of cysteine substitutions on ZPM modulation of I GABA
The effects of the mutations on ZPM modulation of I GABA were also examined.
Nine out of the 22 mutations altered ZPM max potentiation of I GABA (Figs 2, 3, 4, Table   2 ). Figs. 3C and 4C). Previously, we reported that γ E189C had no effect on ZPM potentiation . The differences in results are likely due to using higher concentrations of ZPM used in this study. While potentiation of I GABA (efficacy), the mutations had little to no effect on ZPM apparent binding affinity (K i , Table 2 ).
Effects of cysteine substitutions on DMCM modulation of I GABA
For a subset of mutations (αF99C, 
Changes in BZD modulation of I GABA are not correlated to changes in GABA EC 50
This article has not been copyedited and formatted. The final version may differ from this version. Taken together, these data indicate that the observed changes in GABA EC 50 are not causative for the observed alterations in the efficacies of BZD site positive modulators (Fig. 4) .
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DISCUSSION
We identified four residues in the BZD binding pocket that specifically contribute to BZD-site agonist efficacy: in loop B, A160; in loop C, T206; in loop E, R144; and in loop F, R197 (Fig. 6 , Top row). Mutating these residues significantly disrupted the abilities of ZPM, ESZ and FZM to potentiate I GABA but had little to no effect on high affinity binding (Table 2 ) . Consistent with the mutations having little effect on binding, these residues are largely localized at the periphery of the binding pocket ( Fig. 6C ) and thus, are in an ideal position to propagate local movements in the BZD binding pocket outward to more distant regions of the protein involved in modulating I GABA . We also identified two residues (αV211 and γ E189) that when mutated significantly increased ZPM potentiation of I GABA without affecting FZM or ESZ potentiation indicating that the residues involved in coupling high affinity BZD binding to potentiation of I GABA can be different depending upon the type of BZD-site ligand bound. This is consistent with our previous data, where we demonstrated that structural determinants for high affinity binding of ESZ and ZPM are different . One can envision that depending on the orientation of the BZD in the binding pocket and its contact residues that some of the residues involved in the initial coupling of binding to potentiation of I GABA may differ.
ZPM binding is largely dependent on shape recognition and in silico docking has revealed that ZPM can adopt multiple orientations in the site . 
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We also identified three residues (αG200, γ M130 and γ R132) that specifically mediate high affinity BZD agonist binding. In contrast to the residues discussed above, mutating these residues had no significant effects on BZD agonist efficacy but significantly altered their binding (Fig. 6, middle with glutamate decreases ZPM binding affinity (Schaerer et al., 1998) . Mutating (Fig. 1D ) with a methionine increases the binding affinity of a variety of classical BZDs (Wingrove et al., 1997) .
Here, we also identified residues that are important for both high affinity BZD agonist binding and BZD efficacy: Table 2 ). The binding of ZPM and ESZ to α D97C and α Y209C containing receptors was so disrupted, their binding affinities could not be reliably measured . These residues are located in the back of the BZD binding pocket in loop A (D97 and F99), the side of the pocket in loop B (G157) and at the base of loop M OL #69542
C facing directly into the binding site (Y209) (Fig. 6I) . α H101 has been previously shown to be important for binding of ZPM (Wieland and Luddens, 1994; Wieland et al., 1992) , zopiclone (the racemate of ESZ) (Davies et al., 1998) , flunitrazepam (Berezhnoy et al., 2004) , and diazepam (Berezhnoy et al., 2004; Davies et al., 2000) . Mutation of α H101 to arginine has also been shown to alter BZD efficacy (Benson et al., 1998) . Previous studies have also (Benson et al., 1998; Mihic et al., 1994) . How these mutations result in M OL #69542 switches in a BZD's actions is not clear. Many structurally diverse ligands bind to the BZD binding site indicating the site can accommodate a variety of ligands. We speculate that the mutations may alter the positioning of the drug in the site and/or positioning of nearby residues, which then induces different downstream allosteric rearrangements.
Previously, we identified residues and regions in the γ 2 subunit, outside of the BZD binding pocket, that were critical for coupling BZD agonist binding to potentiation of I GABA actions but were not involved in coupling DMCM binding to inhibition of I GABA (Boileau and Czajkowski, 1999; Kloda and Czajkowski, 2007) . Here, none of the mutations we tested significantly altered the inhibitory abilities of DMCM ( ( Ghanouni et al., 2001; Swaminath et al., 2005; Swaminath et al., 2004) . In summary, the data in this study provide substantial new insights into the structural determinants important for BZD allosteric modulation of GABA A receptor function. Our results, which identify residues within the BZD binding site that encode BZD efficacy versus affinity, will aid in the design of more efficacious and selective drugs. 
